Adults 18 to 65, any sex, with Current Every Day Smoker. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Modified Dot-probe TaskPrimary· Up to 8 weeks post-training
Modified dot-probe task evaluated by using 2 (group: ABM vs. sham) X 3 (session: baseline, 1-day post-training, and 8-weeks post-training) linear mixed model using RT difference scores (neutral-cigarette) as the dependent measures and subject as the random effect.
Baseline
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
5.49
± 0.99
Arm II: Sham Training
7.49
± 1
1-day post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
2.42
± 1.04
Arm II: Sham Training
9.85
± 1.03
8-weeks post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
4.94
± 1.19
Arm II: Sham Training
9.48
± 1.14
Smoking Stroop TaskPrimary· Up to 8 weeks post-training
The Stroop task will consist of three blocks, with a 5-s rest period between blocks: (a) practice (40 trials), (b) neutral words (80 trials), and (c) smoking words (80 trials). The score will be calculated by taking the mean RT difference between the smoking and neutral words on trials with correct responses within the response window.
Baseline
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
-6.57
± 4.11
Arm II: Sham Training
4.94
± 4.15
1-day post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
-2.38
± 4.31
Arm II: Sham Training
3.73
± 4.29
8-weeks post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
-4.59
± 4.94
Arm II: Sham Training
10.97
± 4.7
Cigarette Per Day (CPD)Secondary· Up to 8 weeks post-training
Mean number of cigarettes per day smoked for the seven days preceding each time point.
Baseline
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
18.1
± 0.8
Arm II: Sham Training
18.45
± 0.81
1-day post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
14.94
± 0.82
Arm II: Sham Training
14.78
± 0.83
8-weeks post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
8.29
± 0.9
Arm II: Sham Training
7.52
± 0.87
Expired Carbon Monoxide (CO)Secondary· Up to 8 weeks post-training
Mean expired carbon monoxide, in ppm (parts per million), at each time point.
Baseline
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
22.41
± 1.1
Arm II: Sham Training
22.27
± 1.11
1-day post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
22.28
± 1.13
Arm II: Sham Training
22.95
± 1.13
8-day post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
12.54
± 1.24
Arm II: Sham Training
12.99
± 1.19
Urinary CotinineSecondary· Up to 8 weeks post-training
Mean urinary cotinine, measured in ng/mL, at each time point.
Baseline
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
7.11
± .99
Arm II: Sham Training
7.12
± .09
1-Day post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
6.91
± .09
Arm II: Sham Training
6.99
± .09
8-Day post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
6.16
± .12
Arm II: Sham Training
6.61
± .12
Fagerström Test for Nicotine Dependence (FTND)Secondary· Up to 8 weeks post-training
The Fagerström Test for Nicotine Dependence, yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine. Mean Fagerström Test for Nicotine Dependence (FTND) questionnaire score at each time point.
Baseline
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
4.84
± 0.19
Arm II: Sham Training
4.96
± 0.19
1-day post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
4.34
± 0.2
Arm II: Sham Training
4.05
± 0.2
8-weeks post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
2.93
± 0.21
Arm II: Sham Training
2.65
± 0.21
Wisconsin Smoking Withdrawal Scale (WSWS) - CravingSecondary· Up to 8 weeks post-training
Mean Wisconsin Smoking Withdrawal Scale (WSWS) - Craving subscale score at each time point. Participants rate each item on a scale of 0-4 (0=Strongly disagree, 1=Disagree, 2=Feel neutral, 3=Agree, 4=Strongly agree). The subscale to each item is determined on how high they agree on the scale. Mean Wisconsin Smoking Withdrawal Scale (WSWS) - Craving subscale score at each time point. For some items, the subscale is determined on how low they agreed. Each score is determined by the mean of each item that applies. Higher means indicate greater withdrawal.
Baseline
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
9.9
± 0.29
Arm II: Sham Training
9.76
± 0.29
1-day post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
8.36
± 0.3
Arm II: Sham Training
8.52
± 0.3
8-weeks post-training
Group
Value
95% CI
Arm I: Attention Bias Modification (ABM) Training
6.92
± 0.34
Arm II: Sham Training
6.73
± 0.32
Adverse events — posted to ClinicalTrials.gov
Time frame: 12 weeks.
Reporting threshold: 1%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This randomized clinical trial studies how well a smartphone-delivered attentional bias modification training works in helping patients quit smoking. Smartphone-delivered attentional bias modification training may help patients quit smoking by reducing the attentional bias (the tendency of one's perception to be affected by their recurring thoughts) towards smoking cues that developed over time as a result of conditioning processes through which smoking cues become important.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
Other trials of Computer-Assisted Smoking Cessation Intervention
Trials testing the same drug.
NCT04194918 — Flexiquit+: Web Program to Promote Smoking Cessation in Sexual and Gender Minority Young Adult Smokers
· Phase 1
· completed
Other recruiting trials for Current Every Day Smoker
Currently open trials in the same condition.
NCT03865472 — rTMS in Promoting Smoking Cessation and Preventing Relapse in Current Smokers
· NA
· active not recruiting
NCT03519451 — Use of a Smartphone Mobile Application (App) to Enhance Smoking Cessation Treatment
· NA
· active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem
· Phase 1, PHASE2
· not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and
· Phase 1
· not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che
· Phase 2
· not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca
· Phase 2
· not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar
· Phase 1
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 7 March 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02224391.